Core Viewpoint - The company has proposed a capital market value enhancement plan for 2025-2027, focusing on increasing dividend payouts, optimizing shareholder structure, and implementing long-term incentive mechanisms for management [1] Group 1: Capital Market Value Enhancement Plan - The company aims to use no less than 50% of its annual net profit attributable to shareholders for dividends from 2025 to 2027, barring special circumstances [1] - The company plans to attract high-quality long-term institutional investors to improve market liquidity and trading activity [1] - A core management equity incentive plan will be implemented, with performance indicators covering both revenue and profit growth for 2025-2027 [1] Group 2: Shareholder Structure Optimization - As of June 25, 2025, CPE has reached agreements to sell approximately 51 million shares (about 21.77% of total shares), with investors including foreign long-term healthcare funds and leading international hedge funds [1] - The exit of CPE is expected to alleviate upward pressure on the company's stock price and enhance market liquidity through the entry of long-term funds [1] Group 3: Business Growth and M&A Opportunities - The company has shown stable internal growth, with a 14.5% year-on-year increase in rights fees to 510 million yuan and a 9.7% increase in sales to 550 million yuan during the Goddess Festival promotion [1] - The company plans to increase its stake in Nairui by investing 100 million yuan to acquire 20% of its shares, raising its ownership to 90% [1] - The company is positioned to potentially acquire other leading beauty brands to further increase market share and performance [1] Group 4: Profit Forecast - The company has adjusted its profit forecast, expecting net profits attributable to shareholders to be 290 million, 340 million, and 380 million yuan for 2025-2027, representing year-on-year growth of 25%, 17%, and 14% respectively [2] - The corresponding price-to-earnings ratios based on the closing price on July 3 are projected to be 22, 19, and 16 times for the respective years [2]

Company Overview - Meili Tianyuan Medical Health reported a total revenue of 2.572 billion yuan for the year ending December 31, 2024, representing a year-on-year growth of 19.91% [1] - The net profit attributable to the parent company was 228 million yuan, with a year-on-year increase of 5.94% [1] - The gross profit margin stood at 46.26%, while the debt-to-asset ratio was 77.2% [1] Stock Performance - As of May 22, the stock price of Meili Tianyuan Medical Health closed at 19.3 HKD per share, reflecting a rise of 7.34% with a trading volume of 779,000 shares and a turnover of 14.57 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 7.66%, but year-to-date, it has only risen by 1.01%, underperforming the Hang Seng Index by 18.78% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -21.43 times, with a median of 0.3 times [2] - Meili Tianyuan Medical Health has a P/E ratio of 17.18 times, ranking 29th in the industry [2] - Other companies in the sector have varying P/E ratios, with Juxing Medical Holdings at 0.23 times, Jingjiu Health at 0.38 times, Yongsheng Medical at 3.97 times, Global Medical at 4.67 times, and Ruici Medical at 5.5 times [2] Company Background - Established in 1993, Meili Tianyuan is one of the long-standing domestic chain brands in China's beauty and health management service industry [2] - The company has developed three emerging brands: Beili Shi, Yanyuan, and Xiuker [2] - As of June 30, 2022, the company operates a service network of 352 stores, including 177 directly operated and 175 franchised stores, covering 100 cities nationwide [2]